Stay updated with breaking news from Garya Lyons. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lisanti Capital Growth LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,590 shares of the company’s stock, valued at approximately $1,282,000. Other institutional investors have also modified their holdings […]
Geode Capital Management LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,523,408 shares of the company’s stock after purchasing an additional 87,671 shares during […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for Neurocrine Biosciences in a report released on Wednesday, November 1st. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn $4.85 per share for the year, up from their prior forecast of […]
AtonRa Partners decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 6.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,855 shares of the company’s stock after selling 456 shares during the period. Neurocrine […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lifted by BMO Capital Markets from $100.00 to $111.00 in a report released on Wednesday morning, Marketbeat Ratings reports. BMO Capital Markets currently has a market perform rating on the stock. Several other equities research analysts have also weighed in on the company. Jefferies Financial […]